Amyris (AMRS) Stock: Should You Buy The Dip?


Amyris Inc (NASDAQ: AMRS)

Amyris has been an incredibly interesting stock to watch as of late, and for good reason. The company has had an incredible year, filled with new agreements, and even product launches. However, investors are still wary, so there’s been a bit of volatility. At the moment, the stock is falling off of recent highs. While the movement may be concerning to some, many are wondering if this is an opportunity. In all reality, this definitely could be an opportunity. Today, we’ll talk about what AMRS has accomplished thus far in the year 2016, what we saw in the market last week, and what I’m expecting to see from the stock ahead.

AMRS Has Had An Amazing Year Fundamentally

On a fundamental level, the year 2016 is proving to be an incredibly positive one for Amyris. Throughout the year, the company has signed multiple agreements, launched products, and more. Here’s what I believe to be a list of the most important announcements the company has made throughout the year:

  • The Illuminator Launch – AMRS has been working with a company known as Biossance. The goal of their collaboration was to pioneer a product that reduces dark circles and puffiness around the eyes while rejuvenating the delicate skin in the area around the eyes. That product became known as the Illuminator, and now the product is on the market. Not only is the product out there, it has received big endorsements from key makeup artists and more. All in all, this product is likely to lead to strong revenue for the company ahead.
  • DOE Agreement – On the agreements side of the coin, the company announced an agreement with the United States Department of Energy earlier in the year. Under this agreement, AMRS is working to produce a key ingredient in biofuels, cellulose-derived farnesene.
  • Gevaudan – In the most recent announcement, we learned that Amyris and Givaudan have joined forces. Givaudan is a global leader in the flavors and fragrances industry. Under the collaboration agreement between the two companies, they will be working to develop proprietary fragrance ingredients.
  • Biogen – Finally, we get to Biogen. Earlier in the year, the company announced that it would start working with Biogen. The goal of this collaboration is to use advanced microbe engineering technology to evaluate and develop multiple host microorganisms. Once developed, the ultimate goal is that these microorganisms will be used as alternatives to mammalian cell lines for the production of therapeutic recombinant proteins.

What We’ve Seen From The Stock Throughout The Week

While AMRS has been headed up recently, last week wasn’t a good week for the market. Throughout the week, the stock fell from recent highs of $0.56 per share to $0.48 per share by the end o the trading session on Friday. Nonetheless, in after-hours trading, we’re starting to see some positive news. At the moment, the stock is trading at $0.49 per share after a gain of 1.24% in after-hours.

What I’m Expecting To See Moving Forward

Moving forward, I have a relatively bullish opinion of what we can expect to see from Amyris. At the end of the day, the company has laid the foundation for massive growth throughout the year 2016. As a result, I’m expecting that the company will make its way to profitability in early to mid-2017. Ultimately, this will likely lead to investor excitement and strong gains ahead.

What Do You Think?

Where do you think AMRS is headed moving forward? Join the discussion in the comments below!

[Image Courtesy of Pixabay]


Please enter your comment!
Please enter your name here